Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.

Abstract

BACKGROUND:

Incidence of a fracture, particularly in the hip joint, is high in Parkinson's disease (PD), owing to the immobilisation-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The authors previously demonstrated the lowered incidence of hip fractures in PD by daily administration of risedronate and vitamin D.

METHODS:

This randomised, double-blind, placebo-controlled study was conducted to determine the efficacy of 17.5 mg once-weekly risedronate in the prevention of hip fracture in women with PD. Patients were randomly assigned to 17.5 mg risedronate once a week (n=136) or a placebo (n=136) combined with daily 1000 IU of ergocalciferol. Incidence of hip fractures was compared between the two groups during the 2-year follow-up.

RESULTS:

Hip fractures occurred in 15 patients in the placebo group and 3 patients in the risedronate group. The RR for hip fractures in the risedronate group as compared with the placebo group was 0.20 (95% CI 0.06 to 0.66). In the risedronate group, serum calcium levels decreased during the follow-up, while the levels in the placebo group increased. BMD increased by 3.4% in the risedronate group and decreased by 3.2% in the placebo group (p<0.01).

CONCLUSIONS:

Treatment with once-weekly risedronate and ergocalciferol prevents hip fractures in older women with PD.

• Authors: Yoshihiro Sato, Jun Iwamoto, Yoshiaki Honda
• Journal: Journal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 82 Issue 12 Pg. 1390-3 (Dec 2011) ISSN: 1468-330X [Electronic] England
• PMID: 21825080 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Retracted Publication)

Chemical References

• Bone Density Conservation Agents
• Ergocalciferols
• Risedronic Acid
• Etidronic Acid
• Calcium

Topics

• Aged
• Aged, 80 and over
• Bone Density (drug effects)
• Bone Density Conservation Agents (administration & dosage, therapeutic use)
• Calcium (blood)
• Drug Administration Schedule
• Drug Therapy, Combination (adverse effects, methods)
• Ergocalciferols (administration & dosage, therapeutic use)
• Etidronic Acid (administration & dosage, analogs & derivatives, therapeutic use)
• Female
• Hip Fractures (blood, complications, drug therapy, prevention & control)
• Humans
• Parkinson Disease (blood, complications, drug therapy)
• Risedronic Acid